Clinical Trials
36 trialsCAR-p40-T
Shenzhen University General Hospital
IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL
University of Texas Southwestern Medical Center
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Shenzhen Geno-Immune Medical Institute
CAR-T Cell Therapy Targeting to CD19 for R/R ALL
The First Affiliated Hospital of Soochow University
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Fred Hutchinson Cancer Center
A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
ResCPa
University Hospital Tuebingen
CAR-T
Shenzhen University General Hospital
PACMAN
Princess Maxima Center for Pediatric Oncology
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
CARsgen Therapeutics Co., Ltd.
Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases
Capital Medical University
A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma
Shanghai AbelZeta Ltd.
A Study of RD14-01 in Patients With Advanced Solid Tumors
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
ImmunoBreast - A Phase Ib Study
Odense University Hospital
Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma
AGC Biologics S.p.A.
Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions
Zhejiang University
CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients
Fuda Cancer Hospital, Guangzhou
CAR-T Cell Immunotherapy for HCC Targeting GPC3
Fuda Cancer Hospital, Guangzhou
CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients
Fuda Cancer Hospital, Guangzhou
Vemurafenib and TIL Therapy for Metastatic Melanoma
Herlev Hospital
ISIKOK-19
Acibadem University
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Shenzhen BinDeBio Ltd.
Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
Shenzhen Geno-Immune Medical Institute
TCR-CRC-001
Oslo University Hospital
CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
Wuhan Sian Medical Technology Co., Ltd
Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC
The First Affiliated Hospital of Guangdong Pharmaceutical University
CARTEPC
First Affiliated Hospital of Chengdu Medical College
A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application
The Second Hospital of Nanjing Medical University
A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
Shanghai GeneChem Co., Ltd.
CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies
National University Hospital, Singapore
CART33
Chinese PLA General Hospital
CART-138
Chinese PLA General Hospital